Micron Biomedical

Executive Summary

Micron Biomedical is a private, Phase 2-stage drug delivery company based in Atlanta, GA, pioneering needle-free, thermostable vaccine and therapeutic delivery using dissolvable microneedle patches. Founded in 2013, the company aims to eliminate cold chain requirements and needle-based administration, enabling easier access to medicines in low-resource settings. Targeting infectious diseases and chronic conditions, Micron's platform has the potential to transform global immunization and drug delivery. With a focus on patient-centric, painless administration and improved stability, its lead candidates are in Phase 2 clinical trials. The company's proprietary technology addresses key barriers in vaccine logistics and patient compliance, positioning it as a disruptive force in the pharmaceutical industry. While financial details are undisclosed, the company's advanced stage and strong value proposition merit attention.

Upcoming Catalysts (preview)

• Q4 2026Phase 2 clinical data readout for lead microneedle vaccine candidate60% success
• 2026Strategic partnership with major pharmaceutical or public health organization50% success
• Q2 2027Series C funding round to support Phase 3 development70% success